Why the study?
The review aimed to summarize the state of the art in von Willebrand disease treatment, focusing on specific clinical settings and the use of a VWF concentrate with low FVIII content.
Does von Willebrand factor concentrate with low FVIII content improve management in patients with inherited von Willebrand disease requiring surgical or secondary long-term prophylaxis?
Does von Willebrand factor concentrate with low FVIII content improve management in patients with inherited von Willebrand disease requiring surgical or secondary long-term prophylaxis?
Expert consensus suggests that VWF concentrates with low FVIII content are useful for managing VWD patients at high thrombotic risk or requiring long-term prophylaxis.
Answers are grounded in this paper and cite their sources.
May support low-FVIII VWF concentrate use in high-thrombotic-risk VWD; leaves open prospective confirmation before practice change.
OBJECTIVES: The present review aims to summarize the state-of-the-art von Willebrand disease (VWD) treatment focusing on specific clinical settings (obstetrics, surgery, long-term prophylaxis and comorbidities) as well as on the use of a Von Willebrand factor (VWF) concentrate with low FVIII content. METHODS: Literature research and case reports. RESULTS AND CONCLUSIONS: Considering that patients affected by VWD have an intact ability to synthesize FVIII, in order to avoid excessive levels of FVIII, a highly purified plasma VWF concentrate with low FVIII content could be particularly useful in those patients and clinical circumstances at high thrombotic risk as well as for long-term prophylaxis. When deciding the optimal therapeutic strategy, physicians should take into account both the patient's history and the differences among available concentrates according to the clinical situations requiring treatment.
No takes yet. Share an insight, caveat, or question.
Castaman et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: